Announced details
Treatment of intestinal ganglion cell paucity; regenerative medicine products and cell therapy
Safety and efficacy will be evaluated. Specific quantitative effects are Not disclosed.
S-Quatre and Kyushu University jointly applied for the research project. S-Quatre is participating as a co-investigator and will provide expertise in SHED manufacturing and quality control, as well as cell manufacturing and clinical development.
Associate Professor Koichiro Yoshimaru (吉丸 耕一朗) of the Department of Pediatric Surgery at Kyushu University Hospital is the principal investigator. Other information on the location, representative, capital, year of establishment and business activities is Not disclosed.
Japan Agency for Medical Research and Development (AMED)
Information on the impact on business performance is Not disclosed.
The company does not address Contract Value / Offering price.
Japan Agency for Medical Research and Development (AMED), “Research Projects Selected under the FY2026 Comprehensive Research Program for Overcoming Pediatric Diseases”; Nanbyou Information Center
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stem cells from human exfoliated deciduous teeth (SHED) |
| Counterparty | National University Corporation Kyushu University (Kyushu University Hospital) |
| Counterparty overview | Associate Professor Koichiro Yoshimaru (吉丸 耕一朗) of the Department of Pediatric Surgery at Kyushu University Hospital is the principal investigator. Other information on the location, representative, capital, year of establishment and business activities is Not disclosed. |
| Relationship with the Company | S-Quatre and Kyushu University jointly applied for the research project. S-Quatre is participating as a co-investigator and will provide expertise in SHED manufacturing and quality control, as well as cell manufacturing and clinical development. |
| Applicable area | Treatment of intestinal ganglion cell paucity; regenerative medicine products and cell therapy |
| Awarding / certifying body | Japan Agency for Medical Research and Development (AMED) |
| Quantitative Effects | Safety and efficacy will be evaluated. Specific quantitative effects are Not disclosed. |
| Impact on Business Performance | Information on the impact on business performance is Not disclosed. |
| Source | Japan Agency for Medical Research and Development (AMED), “Research Projects Selected under the FY2026 Comprehensive Research Program for Overcoming Pediatric Diseases”; Nanbyou Information Center |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To open up new treatment possibilities for intestinal ganglion cell paucity, for which effective treatment options are limited, and to deliver meaningful options to patients and their families at an early stage.